Effect of probiotics on non-alcoholic fatty liver disease

Journal of International Pharmaceutical Research

Volumn 41, Issue 5, 2014, Pages 548-551

  Yao, Xiao Min ^a   Qu, Jun Ge ^a   Lin, Ai Bin ^a   Li, Hong Wei ^a  

^a ZHEJIANG PHARMACEUTICAL COLLEGE   (China)

Author keywords

Gut microbes; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Probiotics

Indexed keywords

PROBIOTIC AGENT;

ARTICLE; DISEASE ASSOCIATION; HUMAN; INTESTINE FLORA; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY;

EID: 84916226122     PISSN: 16740440     EISSN: None     Source Type: Journal    
DOI: 10.13220/j.cnki.jipr.2014.05.008     Document Type: Article

References (32)

1. Kelishadi R, Poursafa P. Obesity and air pollution: global risk factors for pediatric non-alcoholic fatty liver disease [J].Hepat Mon, 2011, 11(10):794-802.
2. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears [J]. J Hepatol, 2008, 48 (Suppl. 1):S104-S112.
3. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery [J] J Hepatol, 2006, 45 (3) #600-606.
4. Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects [J]. Am J Gastroenterol, 2007, 102(2) #399-408.
5. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagn - osis and during follow-up in an Italian population [J]. Dig Dis Sci, 1997, 42(7): 1428-1432.
6. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective [J]. Semin Liver Dis, 2008, 28(4): 339-350.
7. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbio- ticsapproaching a definition [J]. Am J Clin Nutr, 2001, 73 (2 Suppl): 361S-364S.
8. Day CP, James OF. Steatohepatitis: a tale of two “hits”? [J]. Gastroenterology, 1998, 114(4): 842-845.
9. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of nonalcoholic fatty liver disease [J]. QJM, 2010, 103(2):71-83.
10. Vanderhoof JA, Whitney DB, Antonson DL, et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children [J]. J Pediair, 1999, 135(5): 564-568.
11. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus [J]. Lett Appl Microbiol, 2007, 45(4): 454-460.
12. Johnson-Henry KC, Donato KA, Shen-Tu G, et al. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function [J]. InfectFmmun, 2008, 76(4): 1340-1348.
13. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen liver interactions and possible role for probiotics [J]. J Hep atol, 2003, 3 8 (4): 681-687.
14. Kelishadi R1, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic fatty liver disease: a systematic review on the current evidences [J].Hepat Mon, 2013, 13(4): e7233.
15. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells [J].JHepaiol, 2008, 49 (5): 821-830.
16. Esposito E, Iacono A, Bianco G, et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats [J]. J Nutr, 2009, 139(5): 905-911.
17. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease [[J].Hepatology, 2003, 37(2): 343-350.
18. Meyer AL, Elmadfa I, Herbacek I, et al. Probiotic, as well as conventional yogurt, can enhance the stimulated production of proin - flammatory cytokines [J].J Hum Nutr Diet, 2007, 20 (6): 590-598.
19. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice [J]. Hep- atology, 2009, 49 (3): 989-997.
20. An HM, Park SY, Lee do K, et al. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats [J]. Lipids Health Dis, 2011, 10(1): 116.
21. Karahan N, Isler M, Koyu A, et al. Effects of probiotics on methionine choline deficient diet-induced steatohepatitis in rats [J]. Turk J Gastroenterol, 2012, 23(2): 110-121.
22. Lee HY, Park JH, Seok SH, et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice [J].Bio- chim Biophys Acta, 2006, 1761(7): 736-744.
23. WangY, XuN, XiA, et al. Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet [J]. Appl Microbiol Biotechnol, 2009, 84(2): 341-347.
24. Paik HD, Park JS, Park E. Effects of Bacillus polyfermenticus SCD on lipid and antioxidant metabolisms in rats fed a high-fat and high-cholesterol diet [J]. Biol Pharm Bull, 2005, 28 (7): 12701274.
25. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic Dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats [J].Nutrition, 2007, 23 (1): 62-68.
26. Eslamparast T, Eghtesad S, Hekmatdoost A, et al. Probiotics and nonalcoholic fatty liver disease [J]. Middle East J Dig Dis, 2013, 5 (1): 129-136.
27. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases [J].J Clin Gastroenterol, 2005, 39(6):540-543.
28. Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium long- um with Fructo-oligosaccharides in patients with non-alcoholic steatohepatitis [J]. Dig Dis Sci, 2012, 57(2): 545-553.
29. Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease [J]- JPediatr Gastroenterol Nutr, 2011, 52(6):740-743.
30. Aller R, De Luis DA, Izaola 0, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial [J]. Eur Rev Med Pharmacol Sci, 2011, 15(9): 1090-1095.
31. Loguercio C, De Simone T, Federico A, et al. Gut-liver axis: a new point of attack to treat chronic liver damage [J]. Am J Gastroenterol, 2002, 97(8): 2144-2146.
32. Herbrecht R, Nivoix Y. Saccharomyces cerevisiae fungemia an adverse effect of Saccharomyces boulardii probiotic administration [J]. Clin InfectDis, 2005, 40(11): 1635-1637.